The global malabsorption syndrome market size is expected to be worth USD 3.66 Billion in 2025. It can reach a valuation of USD 5.88 Billion by 2032. The market is anticipated to exhibit a CAGR of 7.00% during the forecast period (2025-2032).
The market growth is driven by the increasing number of patients affected by Crohn’s disease, short bowel syndrome, celiac disease, and chronic pancreatitis, and the recognition of doctors of the syndrome. Innovations in diagnostic tools to assess the presence of nutritional deficiencies and changes in diets can contribute to the market growth.
However, the lack of healthcare infrastructure in several countries and the drugs in the development phase can restrain the market growth.
Key Market Insights
The malabsorption syndrome market growth is driven by blood tests for accurate diagnosis, case studies and clinical trials for drug development, and personalized nutritional approaches for precise disease management.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/malabsorption-syndrome-market
Malabsorption Syndrome Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 3.66 Billion |
|
Estimated Value by 2032 |
USD 5.88 Billion |
|
Growth Rate |
7.00% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The rise of gluten intolerance cases due to Crohn’s disease, celiac disease, and others have driven the demand in the malabsorption syndrome market. A similar driver is a surge in lactose intolerance incidents that have led to bloating and discomfort.
The discovery of bacterial fermentation as a major cause of malabsorption of carbohydrates has driven the demand for alternative foods. Development of probiotic enzymes and enzymatic therapies are likely to shape the market demand in the coming years. The integration of Lactobacillus species in probiotics can aim to relieve patients of their symptoms.
Market Opportunity: Personalized Nutrition Using AI
Personalized nutrition approaches for the management of malabsorption syndrome can alleviate the patients of their discomfort. The development of AI platforms that link dietary intake and symptoms for the creatin of customized plans can augur favorably for the market. Suggestions of lactase doses and premium subscriptions can improve the health of patients. On March 26, 2025, FriskAi decided to release a free version of its personalized nutrition platform for individuals looking to change their lifestyle through AI recommendations.
Market Challenge: Regulatory Hurdles to Affect Market Growth
Stringent regulations for the safety of novel drugs and a lack of skilled personnel in the development of accurate tests can impede the market growth. According to 21 CFR § 314.126 outlined by the U.S. FDA, lack of efficacy displayed in clinical trials led to the approval of the drug. This was illustrated by the denial of Zealand Pharma’s glepaglutide. The drug failed to meet the substantial evidence requirement under U.S. FDA guidelines.
Malabsorption syndrome contains symptoms that overlap with other digestive disorders, making it difficult for clinicians to come up with an accurate diagnosis. However, the identification of tropical sprue as a definitive indicator of malabsorption syndrome can turn the tide in favor of growth for the market.
Analyst’s View
Recent Developments
Mayo Clinic Laboratories developed a blood test, serum 7α-hydroxy-4-cholesten-3-one (C4) test, for the accurate diagnosis of bile acid malabsorption on August 12, 2024. The combination of the blood test with a stool sample led to the creation of the malabsorption panel that aims to improve its diagnosis rate.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :